Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial
William T Abraham,Philip B Adamson,Robert C Bourge,Mark F Aaron,Maria Rosa Costanzo,Lynne W Stevenson,Warren Strickland,Suresh Neelagaru,Nirav Raval,Steven Krueger,Stanislav Weiner,David Shavelle,Bradley Jeffries,Jay S Yadav,CHAMPION Trial Study Group,Robert B Bourge,Juan Aranda,Andy Smith,Mariel Jessup,Randy Starling,JoAnn Lindenfeld,Barry Greenberg,Randy Wexler,Ralph D'Agostino Jr,Ralph Lazarra,Jalal Ghali,Alan Miller,Peter Carson,John Teerlink,Wayne Levy,Gene Chung,Mike Gilbert,Carol Scharrer,Ayesha Hasan,Laura Yamokoski,Laura Box,Heidi Staehling,Kristina Johnson,Tanya Welch,Helen Fitzner,Melanie Eley,Laura VanPatten,Shari Boshart,Greg Murphy,Linda Holt,Cecile Mayoralgo,Deanna Shea,Nick Chronos,Rebecca Allen,Salpy Pamboukian,Gina Horton,Karen Roher,William Cotts,Wendy Trocchio,Gary Francis,Betsy Wilson,Alan Neiderman,Cynthia Toot,Amar Patel,Jennifer LaCorte,Barry Weinstock,Ingrid Viera-Fleetwood,Javier Jimenez,Adriana Silva,Daniel Bensimhon,Vivian Garman,William French,Olga Barillas,Brenda Hott,Gina Nesbitt,Darrell Youngman,Donna Collie,Fayaz Shawl,Dawn Shaddinger,A G Kfoury,Michelle Endo,Dana Leach,Lee Goldberg,Faith Pickering,Orvar Jonsson,Karla Reilly,Michael Givertz,Susan Anello,John P Boemer,Karen Dwyer,Andrea Myers,Alain Bouchard,Susan Deramus,Mark Dorogy,Carrie Knott,Charles Parrott,Cheryl Flock,Tift Mann,Lindsey Reddersen,Steven Goldsmith,Debra Lascewski,Kenneth Burnham,Dawn Greenwell,Tom Eagan,Suzanne Frew,Theodore Frank,Connie Dellinger,Darshak Karia,Kannari Murthy,Kathleen Kilgallon,Frances Johnson,Cynthia Larew,Gregory Ewald,Jean Flanagan,Barry Clemson,Marsha Pierson,Brian Jaski,Chris Kohlmyer,Pranav Loyalka,Anita Parker,Guillermo Torre-Amione,Jeannie Arredondo,Michael Mathier,Jessica Pisarcik,Ernest Haeusslein,Shelia McDonagh,Leslie Saxon,Karen Adams,Celeste Williams,Jill Teats,Michael Dickinson,Kim McClain,Mark Reisman,Luba Crawford,Ed Garret,Amanda Lee,Eugene Simoni,Sam Sullin,Gail Snell,Donna Mancini,Paula Williams,Marc Silver,Lauretta Ichniowski,Laura Wrona,Ron Waksman,Sandra Griffin,G Martin Mullen,Mary Lou Baumann,Raymond Benza,Joe Carothers,Roy Small,Linda Bowman,Ronald Freudenberger,Marika Vermeersch,Henry Ferniak,Kathleen O'Donnell,Thomas Nygaard,Joyce White,Barry Bertolet,Terri Tutor,Thomas Heywood,Maria Reyes
DOI: https://doi.org/10.1016/S0140-6736(11)60101-3
2011-02-19
Abstract:Background: Results of previous studies support the hypothesis that implantable haemodynamic monitoring systems might reduce rates of hospitalisation in patients with heart failure. We undertook a single-blind trial to assess this approach. Methods: Patients with New York Heart Association (NYHA) class III heart failure, irrespective of the left ventricular ejection fraction, and a previous hospital admission for heart failure were enrolled in 64 centres in the USA. They were randomly assigned by use of a centralised electronic system to management with a wireless implantable haemodynamic monitoring (W-IHM) system (treatment group) or to a control group for at least 6 months. Only patients were masked to their assignment group. In the treatment group, clinicians used daily measurement of pulmonary artery pressures in addition to standard of care versus standard of care alone in the control group. The primary efficacy endpoint was the rate of heart-failure-related hospitalisations at 6 months. The safety endpoints assessed at 6 months were freedom from device-related or system-related complications (DSRC) and freedom from pressure-sensor failures. All analyses were by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00531661. Findings: In 6 months, 83 heart-failure-related hospitalisations were reported in the treatment group (n=270) compared with 120 in the control group (n=280; rate 0·31 vs 0·44, hazard ratio [HR] 0·70, 95% CI 0·60-0·84, p<0·0001). During the entire follow-up (mean 15 months [SD 7]), the treatment group had a 39% reduction in heart-failure-related hospitalisation compared with the control group (153 vs 253, HR 0·64, 95% CI 0·55-0·75; p<0·0001). Eight patients had DSRC and overall freedom from DSRC was 98·6% (97·3-99·4) compared with a prespecified performance criterion of 80% (p<0·0001); and overall freedom from pressure-sensor failures was 100% (99·3-100·0). Interpretation: Our results are consistent with, and extend, previous findings by definitively showing a significant and large reduction in hospitalisation for patients with NYHA class III heart failure who were managed with a wireless implantable haemodynamic monitoring system. The addition of information about pulmonary artery pressure to clinical signs and symptoms allows for improved heart failure management. Funding: CardioMEMS.